Negative Symptoms With Primary Psychotic Disorder

1

Review clinical trials related to Negative Symptoms With Primary Psychotic Disorder. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis

Antipsychotics affects the brain's dopamine system, and the drugs reduce delusions, hallucinations, and disorganized thinking, which are cardinal symptoms of psychotic disorders. However, negative symptoms e.g. anhedonia, avolition, and social withdrawal, as well as cognitive deficits, are not sufficiently treated. Memantine is used to treat Alzheimer's disease and affects the brain's glutamate system. AMEND is a 12-week, double-blind, placebo-controlled, randomized clinical trial (RCT) testing effects of add-on memantine to initial antipsychotic treatment in never-treated patients with first-episode psychosis. The main aim is to reduce negative symptoms. Secondary outcomes are cognition, psychotic symptoms, side effects. Glutamate levels in the brain will be measured before and after 12 weeks using an ultra-high field strength (7 Tesla) magnetic resonance scanner. AMEND will apply rational drug repurposing to optimize treatment of patients experiencing their first psychotic episode.

Participants needed: 46
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Bjorn H. EbdrupUpdated: Dec 9, 2024Locations: 1
Eligibility criteria

Antipsychotic-free(as defined under

Fulfilling the diagnostic criteria of schizophrenia, persistent delusional disor... [+26]